top of page

Antimicrobial Susceptibility Testing Market Size, Share & Growth Forecast 2026–2034

  • 14 hours ago
  • 4 min read

According to Fortune Business Insights, the global antimicrobial susceptibility testing market was valued at USD 4.73 billion in 2025 and is expected to grow from USD 4.97 billion in 2026 to USD 7.38 billion by 2034, registering a CAGR of 5.07% during the forecast period. The market is expanding steadily due to the rising prevalence of antimicrobial resistance (AMR), increasing incidence of infectious diseases, growing adoption of rapid diagnostic technologies, and heightened focus on antimicrobial stewardship programs. Continuous advancements in automated testing systems and increasing investments in healthcare infrastructure are further driving the demand for antimicrobial susceptibility testing solutions across hospitals, diagnostic laboratories, and research institutions worldwide.

The increasing burden of infectious diseases, growing prevalence of drug-resistant bacteria, and rising investments in diagnostic technologies are among the key factors accelerating market expansion. Hospitals, diagnostic laboratories, pharmaceutical companies, and research institutions are increasingly relying on antimicrobial susceptibility testing to identify effective treatment options and improve patient outcomes.

What is Antimicrobial Susceptibility Testing?

Antimicrobial susceptibility testing is a laboratory procedure used to determine how effective antibiotics, antifungal agents, or other antimicrobial drugs are against specific microorganisms. The test helps physicians select the most appropriate therapy while minimizing unnecessary antibiotic usage.

With antimicrobial resistance becoming a significant global public health concern, AST has become an essential component of clinical microbiology laboratories. Rapid and accurate testing enables healthcare providers to prescribe targeted therapies, reducing treatment failures and improving infection control.

Market Growth Drivers

Rising Cases of Antimicrobial Resistance

Antimicrobial resistance has emerged as one of the most pressing healthcare challenges worldwide. Overuse and misuse of antibiotics have accelerated the development of resistant bacterial strains, creating an urgent need for advanced diagnostic solutions.

Healthcare organizations are increasingly adopting antimicrobial susceptibility testing systems to identify resistant pathogens quickly and guide appropriate antibiotic therapy.

Increasing Incidence of Infectious Diseases

The growing number of bacterial, fungal, and hospital-acquired infections continues to fuel demand for diagnostic testing. Conditions such as urinary tract infections, bloodstream infections, respiratory infections, and sepsis require rapid identification of pathogens and their susceptibility profiles.

This increasing disease burden is expected to remain a major driver of market growth throughout the forecast period.

Technological Advancements

Modern AST platforms incorporate automation, artificial intelligence, molecular diagnostics, and rapid testing technologies to deliver faster and more accurate results.

Automated systems reduce manual errors while improving laboratory efficiency. These technological innovations are enabling healthcare providers to initiate targeted treatments much earlier than traditional culture-based methods.

Growing Healthcare Investments

Governments and healthcare organizations across developed and emerging economies are investing heavily in diagnostic infrastructure. Public health initiatives focused on antimicrobial stewardship programs are further supporting the adoption of antimicrobial susceptibility testing solutions.

Market Challenges

Despite strong growth prospects, the antimicrobial susceptibility testing market faces several challenges.

The high cost of automated diagnostic instruments limits adoption among smaller laboratories and healthcare facilities. In addition, stringent regulatory approval processes and the shortage of skilled laboratory professionals continue to impact market expansion.

Furthermore, reimbursement limitations in certain countries may slow the implementation of advanced testing technologies.

Competitive Landscape

The antimicrobial susceptibility testing market remains moderately consolidated, with several leading companies focusing on product innovation, strategic collaborations, and global expansion.

According to Fortune Business Insights, the leading companies include:

  • Bio-Rad Laboratories, Inc.

  • Bruker

  • F. Hoffmann-La Roche Ltd.

  • HiMedia Laboratories

Among these players, Bio-Rad Laboratories, Inc. holds approximately 27% of the global market, making it the industry leader. The company's broad microbiology product portfolio, continuous investment in research and development, and strong global distribution network contribute to its leadership position.

F. Hoffmann-La Roche Ltd. accounts for nearly 22% of the market. Roche continues to strengthen its presence through advanced molecular diagnostics and integrated laboratory solutions designed to improve infectious disease diagnosis.

Together, these two companies control nearly half of the global antimicrobial susceptibility testing market, highlighting the importance of technological innovation and strong product portfolios.

Regional Insights

North America continues to dominate the antimicrobial susceptibility testing market due to its advanced healthcare infrastructure, widespread adoption of automated diagnostic technologies, and strong government initiatives to combat antimicrobial resistance.

Europe also represents a significant market, supported by strict antimicrobial stewardship programs, increasing healthcare spending, and well-established clinical laboratory networks.

Meanwhile, the Asia Pacific region is expected to witness the fastest growth during the forecast period. Rising healthcare investments, expanding diagnostic laboratory capacity, growing awareness regarding antimicrobial resistance, and increasing infectious disease prevalence are driving market growth across countries such as China, India, and Japan.

Latin America and the Middle East & Africa are also experiencing gradual market expansion as healthcare infrastructure continues to improve.

Future Outlook

The future of the antimicrobial susceptibility testing market appears promising as healthcare providers increasingly prioritize precision diagnostics and antimicrobial stewardship.

Emerging technologies such as artificial intelligence, machine learning, next-generation sequencing, and rapid molecular diagnostics are expected to transform microbial identification and susceptibility testing over the coming years.

In addition, collaborations between diagnostic companies, healthcare providers, and pharmaceutical manufacturers are likely to accelerate innovation and improve patient care worldwide.

As antimicrobial resistance continues to pose significant global health risks, demand for accurate, rapid, and automated susceptibility testing solutions is expected to remain strong. Continuous technological advancements and increasing investments in laboratory diagnostics will play a critical role in shaping the future of this market.



Conclusion

The global antimicrobial susceptibility testing market is on a steady growth trajectory, expanding from USD 4.73 billion in 2025 to an estimated USD 7.38 billion by 2034, at a 5.07% CAGR, according to Fortune Business Insights.

Growing concerns over antimicrobial resistance, increasing infectious disease cases, expanding healthcare infrastructure, and continuous technological innovations are expected to drive long-term market growth. Industry leaders such as Bio-Rad Laboratories, Inc. and F. Hoffmann-La Roche Ltd. continue to shape the competitive landscape through innovation and strategic investments, positioning the market for sustained expansion over the next decade.


Contact Information

Fortune Business Insights™ Pvt. Ltd.

Phone:

U.S.: US +1 833 909 2966 (Toll Free)

UK +44 808 502 0280 (Toll Free)

APAC +91 744 740 1245


 
 
 

Comments

bottom of page